DIVISLAB:NSE:NSE-Divi's Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 5516.55

Change

-1.15 (-0.02)%

Market Cap

USD 1,513.85B

Volume

0.39M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
CIPLA:NSE Cipla Limited

+17.95 (+1.28%)

USD 1,191.84B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+48.45 (+1.65%)

USD 1,023.22B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+6.25 (+0.56%)

USD 970.36B
MANKIND:NSE Mankind Pharma Ltd

+4.05 (+0.18%)

USD 960.38B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

+15.80 (+1.81%)

USD 890.87B
LUPIN:NSE Lupin Limited

+56.90 (+2.91%)

USD 868.96B
AUROPHARMA:NSE Aurobindo Pharma Limited

+41.25 (+3.92%)

USD 639.93B
ABBOTINDIA:NSE Abbott India Limited

-91.80 (-0.29%)

USD 633.57B
ALKEM:NSE Alkem Laboratories Limited

+81.85 (+1.77%)

USD 593.38B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

+53.75 (+4.03%)

USD 373.94B

ETFs Containing DIVISLAB:NSE

KMED 0.00 % 0.79 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.16% 79% B- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.16% 79% B- 80% B-
Trailing 12 Months  
Capital Gain 55.63% 90% A- 93% A
Dividend Return 0.85% 63% D 60% D-
Total Return 56.48% 90% A- 93% A
Trailing 5 Years  
Capital Gain 146.27% 42% F 43% F
Dividend Return 4.91% 50% F 32% F
Total Return 151.18% 43% F 42% F
Average Annual (5 Year Horizon)  
Capital Gain 16.14% 30% F 27% F
Dividend Return 16.76% 30% F 27% F
Total Return 0.62% 64% D 49% F
Risk Return Profile  
Volatility (Standard Deviation) 39.05% 65% D 63% D
Risk Adjusted Return 42.92% 36% F 26% F
Market Capitalization 1,513.85B 100% F 98% N/A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector